

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
Karen Chandross	04/23/2008
Lan Lee	04/25/2008
Stefanie Keil	04/28/2008
Matthias Urmann	04/30/2008
Hans Matter	04/30/2008
Wolfgang Wendler	05/06/2008
Maike Glien	05/08/2008
Patrick Bernardelli	05/19/2008
Corinne Terrier	05/19/2008
Herve Minoux	05/19/2008

**RECEIVING PARTY DATA**

Name:	sanofi-aventis
Street Address:	174 Avenue de France
City:	Paris
State/Country:	FRANCE
Postal Code:	75013

**PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	12474838

**CORRESPONDENCE DATA**

Fax Number: (908)231-2626  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
 Phone: 908-231-3582  
 Email: linda.remer@sanofi-aventis.com  
 Correspondent Name: Jiang Lin  
 Address Line 1: 1041 Route 202-206

CH \$40.00 12474838

**500978966**

**PATENT  
 REEL: 023320 FRAME: 0260**

Address Line 2: Mail Code: D303-A  
Address Line 4: Bridgewater, NEW JERSEY 08807

ATTORNEY DOCKET NUMBER:	DE2005/043 US CNT 1
-------------------------	---------------------

NAME OF SUBMITTER:	Linda J. Remer
--------------------	----------------

Total Attachments: 4 source=DE2005043USCNTASSIGNMENT#page1.tif source=DE2005043USCNTASSIGNMENT#page2.tif source=DE2005043USCNTASSIGNMENT#page3.tif source=DE2005043USCNTASSIGNMENT#page4.tif
--

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Patrick Bernardelli, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France
- 2) Dr. Stefanie Keil, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Matthias Urmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Hans Matter, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Wolfgang Wendler, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 6) Dr. Maïke Glien, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 7) Karen Chandross, c/o sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA
- 8) Lan Lee, c/o sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA
- 9) Corinne Terrier, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France
- 10) Hervé Minoux, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France

The inventors are citizens of: 1), 9) – 10) France; 2) - 6) Germany; 7) - 8) USA

hereby sell, assign, and transfer unto **sanofi-aventis**,  
a corporation organized under the laws of **France**,  
located at **174 avenue de France, 75013 Paris, France**,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States, executed concurrently herewith

Ser.-No.: **12/055,793**

filed: **March 26, 2008**

entitled: **Phenyl and pyridinyl-1,2,4-oxadiazolone derivatives, processes for their preparation and  
their use as pharmaceutical compositions**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said  
application for Letters Patent, and in and to all divisional or continuation applications that may be  
filed for United States Letters Patent for any of said inventions, and in and to all patents that may  
be granted on the foregoing applications, and I/we hereby agree, whenever requested, to  
communicate to said assignee, its successors and assigns, any facts known to me/us respecting  
said inventions, to testify in any legal proceeding, and to execute all applications or papers  
necessary to obtain and maintain proper patent protection on said inventions in the United States.

**Inventor(s):**

- 1<sup>st</sup>: \_\_\_\_\_ Date: \_\_\_\_\_
- 2<sup>nd</sup>: \_\_\_\_\_ Date: \_\_\_\_\_
- 3<sup>rd</sup>: \_\_\_\_\_ Date: \_\_\_\_\_
- 4<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_
- 5<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_
- 6<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_
- 7<sup>th</sup>: Karen Chandross 4/23/08 Date: \_\_\_\_\_
- 8<sup>th</sup>: [Signature] 4/25/08 Date: \_\_\_\_\_
- 9<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_
- 10<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Patrick Bernardelli, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France
- 2) Dr. Stefanie Keil, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Matthias Urmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Hans Matter, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Wolfgang Wendler, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 6) Dr. Maike Glien, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 7) Karen Chandross, c/o sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA
- 8) Lan Lee, c/o sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA
- 9) Corinne Terrier, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France
- 10) Hervé Minoux, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France

The inventors are citizens of: 1), 9) – 10) France; 2) - 6) Germany; 7) - 8) USA

hereby sell, assign, and transfer unto **sanofi-aventis**,  
a corporation organized under the laws of **France**,  
located at **174 avenue de France, 75013 Paris, France**,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States, executed concurrently herewith

Ser.-No.: **12/055,793**

filed: **March 26, 2008**

entitled: **Phenyl and pyridinyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceutical compositions**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

**Inventor(s):**

1 <sup>st</sup> :	_____	Date:	_____
2 <sup>nd</sup> :	<i>M. Glien</i>	Date:	<i>26.04.2008</i>
3 <sup>rd</sup> :	<i>M. Urmann</i>	Date:	<i>30.4.08</i>
4 <sup>th</sup> :	<i>W. Wendler</i>	Date:	<i>30.04.08</i>
5 <sup>th</sup> :	<i>W. Wendler</i>	Date:	<i>May 6, 2008</i>
6 <sup>th</sup> :	<i>P. Bernardelli</i>	Date:	<i>May 8, 2008</i>
7 <sup>th</sup> :	_____	Date:	_____
8 <sup>th</sup> :	_____	Date:	_____
9 <sup>th</sup> :	_____	Date:	_____
10 <sup>th</sup> :	_____	Date:	_____

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Patrick Bernardelli, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France
- 2) Dr. Stefanie Keil, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Matthias Urmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Hans Matter, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Wolfgang Wendler, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 6) Dr. Maike Glien, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 7) Karen Chandross, c/o sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA
- 8) Lan Lee, c/o sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA
- 9) Corinne Terrier, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France
- 10) Hervé Minoux, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France

The inventors are citizens of: 1), 9) – 10) France; 2) - 6) Germany; 7) - 8) USA

hereby sell, assign, and transfer unto **sanofi-aventis**,  
a corporation organized under the laws of **France**,  
located at **174 avenue de France, 75013 Paris, France**,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States, executed concurrently herewith


Ser.-No.: **12/055,793**

filed: **March 26, 2008**

entitled: **Phenyl and pyridinyl-1,2,4-oxadiazolone derivatives, processes for their preparation and  
their use as pharmaceutical compositions**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said  
application for Letters Patent, and in and to all divisional or continuation applications that may be  
filed for United States Letters Patent for any of said inventions, and in and to all patents that may  
be granted on the foregoing applications, and I/we hereby agree, whenever requested, to  
communicate to said assignee, its successors and assigns, any facts known to me/us respecting  
said inventions, to testify in any legal proceeding, and to execute all applications or papers  
necessary to obtain and maintain proper patent protection on said inventions in the United States.

**Inventor(s):**

1<sup>st</sup>:  Date: May 19<sup>th</sup> 2008

2<sup>nd</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

3<sup>rd</sup>: \_\_\_\_\_ Date: \_\_\_\_\_


4<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

5<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

6<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

7<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

8<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

9<sup>th</sup>:  Date: May 19<sup>th</sup> 2008

10<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

**ASSIGNMENT**

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Patrick Bernardelli, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France
- 2) Dr. Stefanie Keil, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Matthias Urmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Hans Matter, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Wolfgang Wendler, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 6) Dr. Maike Glien, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 7) Karen Chandross, c/o sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA
- 8) Lan Lee, c/o sanofi-aventis U.S. Inc., 55 Corporate Drive, Bridgewater, New Jersey 08807, USA
- 9) Corinne Terrier, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France
- 10) Hervé Minoux, c/o Sanofi-Aventis, Département Brevet, 174, Avenue de France, 75013 Paris, France

The inventors are citizens of: 1), 9) – 10) France; 2) - 6) Germany; 7) - 8) USA

hereby sell, assign, and transfer unto **sanofi-aventis**,  
a corporation organized under the laws of **France**,  
located at **174 avenue de France, 75013 Paris, France**,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States, executed concurrently herewith

Ser.-No.: **12/055,793**

filed: **March 26, 2008**

entitled: **Phenyl and pyridinyl-1,2,4-oxadiazolone derivatives, processes for their preparation and  
their use as pharmaceutical compositions**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said  
application for Letters Patent, and in and to all divisional or continuation applications that may be  
filed for United States Letters Patent for any of said inventions, and in and to all patents that may  
be granted on the foregoing applications, and I/we hereby agree, whenever requested, to  
communicate to said assignee, its successors and assigns, any facts known to me/us respecting  
said inventions, to testify in any legal proceeding, and to execute all applications or papers  
necessary to obtain and maintain proper patent protection on said inventions in the United States.

**Inventor(s):**

1<sup>st</sup>. \_\_\_\_\_ Date: \_\_\_\_\_

2<sup>nd</sup>. \_\_\_\_\_ Date: \_\_\_\_\_

3<sup>rd</sup>. \_\_\_\_\_ Date: \_\_\_\_\_

4<sup>th</sup>. \_\_\_\_\_ Date: \_\_\_\_\_


5<sup>th</sup>. \_\_\_\_\_ Date: \_\_\_\_\_

6<sup>th</sup>. \_\_\_\_\_ Date: \_\_\_\_\_

7<sup>th</sup>. \_\_\_\_\_ Date: \_\_\_\_\_

8<sup>th</sup>. \_\_\_\_\_ Date: \_\_\_\_\_

9<sup>th</sup>. \_\_\_\_\_ Date: \_\_\_\_\_

10<sup>th</sup>.  \_\_\_\_\_ Date: **MAY 19, 2008**

**PATENT**